Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

SciSparc Ltd. - Ordinary Shares (NQ: SPRC )

1.020 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 23,484
Open 1.020
Bid (Size) 0.8976 (1)
Ask (Size) 0.9417 (4)
Prev. Close 1.020
Today's Range 1.020 - 1.020
52wk Range 0.1970 - 6.780
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results
From SciSparc Ltd
Via GlobeNewswire
Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet
Via Benzinga

Performance

YTD
+159.81%
+159.81%
1 Month
+311.62%
+311.62%
3 Month
+366.39%
+366.39%
6 Month
+54.69%
+54.69%
1 Year
-77.18%
-77.18%

More News

Read More
S&P Jumps 1%; Regional Health Properties Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Psychedelic-SciSparc Stock Trading Higher On Monday?
Via Benzinga
Exposures Product Safety
US Stocks Open Higher; Dow Jumps Over 200 Points
Via Benzinga
Topics Stocks
Exposures US Equities
SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment
From SciSparc Ltd
Via GlobeNewswire
SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder
From SciSparc Ltd
Via GlobeNewswire
S&P 500 Edges Lower, SciSparc Shares Surge
Via Benzinga
Topics Stocks
Exposures US Equities
Dow Gains 50 Points, SEALSQ Shares Plummet
Via Benzinga
Topics Stocks
Exposures US Equities
Nasdaq Dips Over 100 Points, US Initial Jobless Claims Fall
Via Benzinga
SciSparc Shares Skyrocket With AutoMax's First JAC Motors Shipment
Via Benzinga
Why Zoomcar Shares Are Trading Higher By Around 142%; Here Are 20 Stocks Moving Premarket
Via Benzinga
SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation
From SciSparc Ltd
Via GlobeNewswire
SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company
From SciSparc Ltd
Via GlobeNewswire
Pharma Company Gets FDA Green Light For Next Phase Trial For Tourette Syndrome
Via Benzinga
Exposures Product Safety
SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment
From SciSparc Ltd
Via GlobeNewswire
SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX
From SciSparc Ltd
Via GlobeNewswire
SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment
From SciSparc Ltd
Via GlobeNewswire
SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment
From SciSparc Ltd
Via GlobeNewswire
Clearmind Medicine Files International Patent For Ibogaine Combination Therapy
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Via Benzinga
SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy
From SciSparc Ltd
Via GlobeNewswire
SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax’s Direct Import Agreement with Major Chinese Vehicle Manufacturer
From SciSparc Ltd
Via GlobeNewswire
SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
From SciSparc Ltd
Via GlobeNewswire
Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.